CN102998455A - Kit for detecting or diagnosing prostatic cancer - Google Patents
Kit for detecting or diagnosing prostatic cancer Download PDFInfo
- Publication number
- CN102998455A CN102998455A CN2012100322580A CN201210032258A CN102998455A CN 102998455 A CN102998455 A CN 102998455A CN 2012100322580 A CN2012100322580 A CN 2012100322580A CN 201210032258 A CN201210032258 A CN 201210032258A CN 102998455 A CN102998455 A CN 102998455A
- Authority
- CN
- China
- Prior art keywords
- catenin
- antibody
- kit
- prostate cancer
- delta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention provides a kit for detecting or diagnosing prostatic cancer, and the kit comprises a delta-catenin adsorption antibody, a coating buffer, a washing buffer, a block buffer, a delta-catenin detection antibody and an enzyme labelled antibody, or comprises a delta-catenin adsorption antibody, a coating buffer, a washing buffer, a block buffer, a delta-catenin detection antibody and a nano-quantum dot mark. According to the kit, delta-catenin protein with high correlation with prostatic cancer can be detected from urine of a patient by using an ELISA (enzyme-linked immuno sorbent assay) method, and the ELISA method is developed with high sensitivity and specification, is non-invasive to a patient, can be repeatedly adopted, and can be accepted by patients; and the nano-quantum dot (QD) labeling method is small in sampling amount, so that changes of delta-catenin protein in the urine can be detected more sensitively by combining the antibody and the QD which are used in the ELISA method. The kit can be used for diagnosing the prostatic cancer.
Description
Technical field
The present invention relates to a kind of kit, be specifically related to the kit of a kind of detection or diagnosing prostate cancer.
Background technology
Prostate cancer (PCa) is one of common cancer, ranking second (Jemal, A., Siegel R, Xu J, Ward E.Cancer statistics, 2010.CA Cancer J Clin 2010.60 (5): 277-300 in the male sex causes death cancer; Lu Q, Zhang J and Chen YH.Prostate cancer cell growth and death:complex roles of pro-and anti-oncogenic protein signaling.2009.In:
Handbook of Prostate Cancer Cell Research(Editor:Alan T.Meridith) .Nova Science Publishers, Inc.431-447;
HesselsD and
SchalkenJA.The use of PCA3 in the diagnosis of prostate cancer.2009.
Nature Reviews Urology.6:255-261).Because the complicacy of prostate cancer performance, early diagnosis prostate gland cancer is difficult.The screening technique of at present clinical extensive employing is to detect serum PSA (PSA), digital examination per rectum (DRE) and through the Ultrasonic Detection (TRUS) of intestines.But the key statistics of PSA experiment shows PSA to the positive predictive value of PCa only 34%, the patient of gray area 4-10 μ g/L 25% PCa that concealment arranged is arranged.The male sex of PSA concentration＜4 μ g/L has 15% PCa is arranged.And benign prostatic hyperplasis (BPH), its PSA also can raise, and can cause unnecessary pathology biopsy and other expensive and uncomfortable aggressive inspection to get involved.As unique prostate cancer blood serum designated object of present clinical employing, PSA has obvious weak point (Hessels D and Schalken JA.The use of PCA3 in the diagnosis of prostate cancer.2009.Nature Reviews Urology.6:255-261).Therefore seek one simple, the mark that PCa specificity, susceptibility, recall rate are increased greatly will produce far-reaching influence to early detection, diagnosis and the treatment of PCa.It is very attractive that the urine biology mark detects, because this can provide one simply, and noninvasive early prostate cancer inspection method, can making widely, the crowd accepts screening.In recent years, the discovery of relevant prostate cancer urine markers has had very large progress.With PCA3 (prostate cancer gene 3) non-coding mRNA and the technical identification of TMPRRS2:ERG fusion a urine biology mark.They need to get urine behind the massage of prostate otherwise positive value is lower.Some other urine biology mark comprises PCADM-1 at present just under study for action, methyl amimoacetic acid, Engrailed gene, minichromosomes 5 albumen, prostatic specific membrane antigen etc.A desirable urine biology mark must satisfy some important standards, namely except distinguishing normal structure and cancerous tissue, prostate cancer pathology is had the support of science, and its detection method should be simply painless, and the clinician is made an explanation to it easily.
δ-Catenin/NPRAP/Neurojungin (the neural albumen that connects of δ-catenin/NPRAP/) is that in β-catenin superfamily adheres to connection albumen (Lu, Q, Paredes M, Medina M, Zhou J, Cavallo R, Peifer M, Orecchio L, Kosik KS.delta-catenin, an adhesive junction-associated protein which promotes cell scattering.
J Cell Biol, 1999.144 (3): 519-532), be accredited as at first the differential protein in the brain tissue.Yet studies show that, compare with benign prostatic hyperplasis, the δ of prostate cancer-catenin mRNA overexpression (Lu Q, Dobbs LJ, Christopher WG, Lanford GW, Revelo MP, Shappell S and Chen YH.Increased expression of δ-catenin/neural plakophilin-related armadillo protein (NPRAP) is associated with the downregulation and redistribution of E-cadherin and p120ctn in human prostate cancer.2005.
Human Pathology.36:1037-1048; Burger, MJ Tebay MA, Keith PA, Samaratunga HM, Clements J, Lavin MF et al., Expression analysis of delta-catenin and prostate-specific membrane antigen:their potential as diagnostic markers for prostate cancer.
Int J Cancer, 2002.100 (2): 228-237).Micro-array tissue studies show that, (PIN) δ in the prostatic intraepithelial neoplasia-catenin expresses and begins to raise, and increase consistent with the Gleason scoring, show that δ-catenin is a potential index (Lu Q of prostate cancer progress, Dobbs LJ, Christopher WG, Lanford GW, Revelo MP, Shappell S and Chen YH.Increased expression of δ-catenin/neural plakophilin-related armadillo protein (NPRAP) is associated with the downregulation and redistribution of E-cadherin and p120ctn in human prostate cancer.2005.
Human Pathology.36:1037-1048; LuQ and Chen YH.Method of detecting cancer using delta-catenin.United StatesPatent:7,445,906.2008).
With prostate cancer tissue sample and the 90 routine normal prostate tissue samples organized after little array TMA analyzes 90 routine prostate excisions, 92% Cap patient specimen demonstrate strong (46/72) or moderate (20/72) δ-catenin dyeing (only have in immunity scoring 〉=2, the 72 routine samples 6 examples (8%) immunity scoring negative or＜2.Having in the 65 routine optimum samples has 6 examples (9%) immunity scoring to equal to have in 2, the 65 routine optimum samples 10 examples (15%) immunity scoring to be higher than 2 in 49 examples (75%) immunity scoring＜2, the 65 routine optimum samples.If showing, these data use separately clinically δ-catenin as evaluation, its susceptibility is 91.7%, specificity is 75.4% (Lu Q, Dobbs LJ, Christopher WG, Lanford GW, Revelo MP, Shappell S and Chen YH.Increased expression of δ-catenin/neural plakophilin-related armadillo protein (NPRAP) is associated with the downregulation and redistribution of E-cadherin and p120
CtnIn human prostate cancer.2005.
Human Pathology.36:1037-1048).Recently one can detect δ-catenin about sedimentary studies show that in people's acellular urine Prostasomes of human urine, and δ-Catenin significantly increases (P＜0.0005) (8) in patient's PCa urine.These are researched and proposed one and are possibility (the Lu Q of the non-invasion and attack detection of patient PCa, Zhang J, Allison R, Gay H, Yang WX, Bhowmick N, Frelix G, Shappell S, Chen YH.Identification of extracellular-catenin accumulation for prostate cancer detection.2009.The Prostate.69 (4): 411-418).
Summary of the invention
The object of the present invention is to provide a kind of simple detection or the kit of diagnosis diagnosing prostate cancer, it mainly comprises δ-catenin absorption antibody, coated damping fluid, lavation buffer solution, sealing damping fluid, δ-catenin detection antibody, enzyme labelled antibody.
The present invention also provides a kind of simple detection or the kit of diagnosis diagnosis of prostate, and it mainly comprises δ-catenin absorption antibody, coated damping fluid, lavation buffer solution, sealing damping fluid, δ-catenin detection antibody, nano-quantum point mark.
In mentioned reagent box provided by the invention, also comprise standard items and negative control.
Wherein said standard items preferably are people δ-catenin standard protein.It is anti-human that described δ-catenin absorption antibody can be rabbit, the mouse-anti people, and anti-human or other δ-catenin antibody of chicken, described δ-catenin antibody dilution to protein content is 1～100 μ g/ml during use.
Described coated damping fluid can be carbonate or dPBS or other buffering agent.
Described lavation buffer solution is preferably dPBS or other buffering agent that contains washing agent.
It is anti-human that wherein said δ-catenin detection antibody can be rabbit, mouse-anti people, anti-human or other δ-catenin antibody of chicken.Preferred δ-catenin identification antibody detects the different δ of antibody recognition-catenin protein sequence from δ-catenin.
The invention still further relates to the application of δ-catenin albumen in the preparation of preparation detection or diagnosing prostate cancer.
Kit provided by the invention can be from patient urine detects the δ that becomes high correlation with prostate cancer-catenin albumen with the ELISA method, and ELISA method maturation, susceptibility and specificity are higher, be noninvasive to patient, can repeat to take that patient takes like a shot.Further, nano-quantum point (QD) labelling method sampling amount is little, and antibody used in the ELISA method is combined with QD, can detect more delicately the variation of δ in the urine-catenin albumen, thereby is used for diagnosing prostate cancer.
For above and other objects of the present invention, feature and advantage can be become apparent, preferred embodiment cited below particularly, and cooperation accompanying drawing are described in detail below.
Description of drawings
Figure 1A-1B is that the ELISA method detects δ in the urine-catenin albumen, and wherein Figure 1A represents purifying standard protein δ-catenin (ng/ml), and Figure 1B is urine δ-catenin integrated enzyme reaction.
Fig. 2 is that the nano-quantum point labelling method detects δ-catenin albumen in the urine.
Embodiment
The invention provides a kind of simple detection or the kit of diagnosing prostate cancer, it mainly comprises δ-catenin absorption antibody, coated damping fluid, lavation buffer solution, sealing damping fluid, δ-catenin detection antibody, enzyme labelled antibody.Perhaps mainly comprise δ-catenin absorption antibody, coated damping fluid, lavation buffer solution, sealing damping fluid, δ-catenin detection antibody, nano-quantum point mark.
Described kit also comprises standard items and negative control.
Following detailed description adopts kit of the present invention to detect or diagnosing prostate cancer.
People δ of the present invention-catenin standard protein is that recombined human δ-catenin albumen, the anti-human δ-catenin antibody of purifying has been disclosed in following document: Paffenholz R, Franke WW.Identification and localization of a neurally expressed member of the plakoglobin/armadillo multigene family.Differentiation.1997Aug; 61 (5): 293-304; Lu Q, Paredes M, Medina M, Zhou J, Cavallo R, Peifer M, Orecchio L, Kosik KS.delta-catenin, an adhesive junction-associated protein which promotes cell scattering.J Cell Biol.1999 Feb 8; 144 (3): 519-32.
Embodiment 1:ELISA method detects δ-catenin albumen in the urine
Step 1: coated (Coat plate)
With carbonate or the coated damping fluid of dPBS δ-catenin being adsorbed antibody dilution to protein content is 1～100 μ g/ml.Add 100 microlitres in the reacting hole of each polystyrene board, 4 ℃ are spent the night.Discard solution in the hole next day, washes 5 times with lavation buffer solution, washes the plate machine washing and wash.
1) coated damping fluid (carbonate buffer solution):
NaCO
31.59 gram
NaHCO
32.93 gram
Adding distil water is to 1000ml
Or Dulbecco ' s PBS (Invitrogen)
2) lavation buffer solution:
KH
2PO
40.2 gram
Na
2HPO
412H
2O 2.9 grams
NaCl 8.0 grams
KCl 0.2 gram
Tween-20?0.05％?0.5ml
Adding distil water is to 1000ml
Step 2: sealing
Every hole adds sealing damping fluid 200 microlitres, hatch 1 hour under the room temperature after.Wash with washing the plate machine washing.
Confining liquid: (Blocking buffer)
Bovine serum albumin(BSA) (BSA) 2 grams
Add lavation buffer solution to 100ml.
Step 3: application of sample
Standard items: people δ-catenin standard protein.
Negative control: normal health adult male urine specimen.
The carcinoma of prostate urine specimen---the prostate cancer patient at 37 example ages 50～80 makes a definite diagnosis Gleason classification 7～10 through the ultrasonic first visit of urological department and pathology.Preserve at-20 degree behind their urine collecting.
Each sample urine respectively adds 100 microlitres, and 37 ℃ of incubations are after 2 hours.Wash plate.
But urine specimen also low-temperature and high-speed (14,000) left the heart 15 minutes, application of sample sediment 3 holes, urine supernatant three holes.
Step 4: add δ-catenin and detect antibody Block liquid dilution, every hole 50 microlitres.Wash plate.
Step 5: add enzyme labelled antibody (goat-anti or other anti--HRP) (U.S. Sigma company)
In each reacting hole, add resisting-HRP enzyme labelled antibody (U.S. Sigma company) of fresh dilution.After the incubated at room 1 hour, wash the plate machine washing and wash.
Step 6: colour developing
In each reacting hole, add TMB (Sigma T0440), room temperature, keep in Dark Place.Or the nitrite ion A of Shanghai Xiamen Kehua and B liquid.
Step 7: cessation reaction
Every hole adds H
2SO
4, cessation reaction.
Step 8: the result judges
Plate reading machine is read plate.
Experiment shows that available DASELISA immunization measures at least following δ-catenin of 2ng in the urine.Shown in Figure 1A-1B, wherein Figure 1A represents purifying standard protein δ-catenin (ng/ml), and Figure 1B is urine δ-catenin integrated enzyme reaction.Can see that from Figure 1B prostate cancer patient urine δ-catenin can reach 3 times of normal person.Use 48 routine prostate cancer patient urines and normal person's test for identification susceptibility can reach 65～85%, specificity can reach more than 90%.
Embodiment 2: the nano-quantum point labelling method detects δ-catenin albumen in the urine
Step 5: the anti-human δ of nano-quantum point mark and step 4-catenin antibody is combined
Adopt the Evitags nano-quantum point of Evident Technologies (Troy, USA New York) water-soluble.Form active with EDC (1-ethyl-3-[3-dimethylaminopropyl] carbodiimide) and sulfo-NHS on the nano-quantum point surface.After unnecessary EDC and sulfo-NHS removes with filtrator, add anti-human δ-catenin antibody and nano-quantum point and form covalent bond.
Step 6: the result judges
As shown in Figure 2, the nano-quantum point labelling experiment shows, nano-quantum point (QD) also can be measured δ in the solution-catenin albumen in conjunction with δ-catenin antibody.
These above tests all proves with δ-catenin antibody desmoenzyme and join or the combining nano quantum dot can detect the variation of the δ that becomes high correlation with prostate cancer-catenin albumen, thereby for diagnosing prostate cancer.
Although the present invention discloses as above with preferred embodiment, so it is not to limit the present invention.In any human or animal's tissue and the various body fluid, as long as there is the δ-catenin albumen of available δ-catenin antibody or δ-catenin antibody and nano-quantum point combination identification, just then δ-catenin antibody desmoenzyme connection or combining nano quantum dot can be used for detecting.Any person of ordinary skill in the field, without departing from the spirit and scope of the present invention, when can doing a little change and improvement, so protection scope of the present invention is as the criterion when looking the claim person of defining.
Claims (9)
1. one kind is detected or the kit of diagnosing prostate cancer, it is characterized in that comprising δ-catenin absorption antibody, coated damping fluid, lavation buffer solution, sealing damping fluid, δ-catenin and detects antibody, enzyme labelled antibody.
2. one kind is detected or the kit of diagnosing prostate cancer, it is characterized in that comprising δ-catenin absorption antibody, coated damping fluid, lavation buffer solution, sealing damping fluid, δ-catenin and detects antibody, nano-quantum point mark.
3. kit according to claim 1 and 2 is characterized in that, also comprises standard items and negative control.
4. kit according to claim 3 is characterized in that, described standard items behaviour δ-catenin standard protein.
5. kit according to claim 1 and 2 is characterized in that, described δ-catenin absorption antibody is δ-catenin antibody.
6. kit according to claim 1 and 2 is characterized in that, described coated damping fluid is carbonate or dPBS.
7. kit according to claim 1 and 2 is characterized in that, described lavation buffer solution is the dPBS that contains washing agent.
8. kit according to claim 1 and 2 is characterized in that, described δ-catenin detects antibody and adsorbs the different δ of antibody recognition-catenin protein sequence with δ-catenin.
9. the application of δ-catenin albumen in the preparation of preparation detection or diagnosing prostate cancer.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210032258.0A CN102998455B (en) | 2012-02-14 | 2012-02-14 | The kit of a kind of detection or diagnosing prostate cancer |
| PCT/CN2013/000118 WO2013120394A1 (en) | 2012-02-14 | 2013-02-04 | Kit for detection or diagnosis of prostate cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210032258.0A CN102998455B (en) | 2012-02-14 | 2012-02-14 | The kit of a kind of detection or diagnosing prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102998455A true CN102998455A (en) | 2013-03-27 |
| CN102998455B CN102998455B (en) | 2016-01-13 |
Family
ID=47927292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210032258.0A Active CN102998455B (en) | 2012-02-14 | 2012-02-14 | The kit of a kind of detection or diagnosing prostate cancer |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN102998455B (en) |
| WO (1) | WO2013120394A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103983791A (en) * | 2014-05-29 | 2014-08-13 | 深圳市柏明胜医疗器械有限公司 | Human CA125 protein quantum dot labeled double-sandwiched immunoassay detection kit |
| CN107522780A (en) * | 2017-10-12 | 2017-12-29 | 南京精竞生物科技有限公司 | A kind of preparation method and applications method of human prostate Immunodominant Antigenic |
| CN112574955A (en) * | 2019-09-29 | 2021-03-30 | 昂科生物医学技术(苏州)有限公司 | Hybridoma cell LCZ9H4, monoclonal antibody secreted by hybridoma cell LCZ9H4 and application of monoclonal antibody |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3304084B1 (en) | 2015-06-08 | 2022-03-23 | Arquer Diagnostics Limited | Methods and kits |
| EP3304082B1 (en) | 2015-06-08 | 2020-05-13 | Arquer Diagnostics Limited | Methods for analysing a urine sample |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1515909A (en) * | 2003-08-27 | 2004-07-28 | 魏景艳 | Quantum point marker sandwich immunodetection method and its diagnosis kit |
| US20050032099A1 (en) * | 2003-06-30 | 2005-02-10 | Qun Lu | Method of detecting cancer using delta-catenin |
| CN102053153A (en) * | 2010-11-25 | 2011-05-11 | 西安微通生物技术有限公司 | Dot immuno gold directed infiltration detection kit and application thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1864134A4 (en) * | 2005-02-07 | 2010-10-20 | Univ Columbia | Methods to treat or prevent hormone-resistant prostate cancer using sirna specific for protocadherin-pc, or other inhibitors of protocadherin-pc expression or activity |
| CN1975425A (en) * | 2006-02-10 | 2007-06-06 | 厦门华侨亚热带植物引种园 | Odntoglossum ringspot virus double-anti sandwich enzyme-linked assay kit and preparation thereof and detecting method |
| US20080081339A1 (en) * | 2006-10-03 | 2008-04-03 | The Brigham And Women's Hospital, Inc. | Tumor associated markers in the diagnosis of prostate cancer |
| WO2009067204A2 (en) * | 2007-11-20 | 2009-05-28 | East Carolina University | Method of screening for cancer by detecting mutations in the delta-catenin gene promoter and 5'-untranslated region |
| CN101532008A (en) * | 2009-04-29 | 2009-09-16 | 朱晓林 | Preparation of anti beta-catenin monoclonal antibody and application thereof in pathologic examination of colon cancer |
| US20140051081A1 (en) * | 2011-03-29 | 2014-02-20 | East Carolina University | Method of screening for cancer by detecting mutations in the delta-catenin coding region |
| CN102266561B (en) * | 2011-07-14 | 2012-10-03 | 南京农业大学 | Application of Wnt/beta-catenin signal channel inhibitor to preparation of medicament for promoting apoptosis |
-
2012
- 2012-02-14 CN CN201210032258.0A patent/CN102998455B/en active Active
-
2013
- 2013-02-04 WO PCT/CN2013/000118 patent/WO2013120394A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050032099A1 (en) * | 2003-06-30 | 2005-02-10 | Qun Lu | Method of detecting cancer using delta-catenin |
| US20090136943A1 (en) * | 2003-06-30 | 2009-05-28 | East Carolina University | Method of detecting cancer using delta-catenin |
| CN1515909A (en) * | 2003-08-27 | 2004-07-28 | 魏景艳 | Quantum point marker sandwich immunodetection method and its diagnosis kit |
| CN102053153A (en) * | 2010-11-25 | 2011-05-11 | 西安微通生物技术有限公司 | Dot immuno gold directed infiltration detection kit and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| QUN LU ET AL.: "Increased expression of d-catenin/neural plakophilin-related armadillo protein is associated with the down-regulation and redistribution of E-cadherin and p120ctn in human prostate cancer", 《HUMAN PATHOLOGY》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103983791A (en) * | 2014-05-29 | 2014-08-13 | 深圳市柏明胜医疗器械有限公司 | Human CA125 protein quantum dot labeled double-sandwiched immunoassay detection kit |
| CN107522780A (en) * | 2017-10-12 | 2017-12-29 | 南京精竞生物科技有限公司 | A kind of preparation method and applications method of human prostate Immunodominant Antigenic |
| CN112574955A (en) * | 2019-09-29 | 2021-03-30 | 昂科生物医学技术(苏州)有限公司 | Hybridoma cell LCZ9H4, monoclonal antibody secreted by hybridoma cell LCZ9H4 and application of monoclonal antibody |
| WO2021056907A1 (en) * | 2019-09-29 | 2021-04-01 | 昂科生物医学技术(苏州)有限公司 | Hybridoma cell lcz9h4, monoclonal antibody secreted therefrom, and application thereof |
| CN112574955B (en) * | 2019-09-29 | 2022-10-25 | 昂科生物医学技术(苏州)有限公司 | Hybridoma cell LCZ9H4, monoclonal antibody secreted by same and application of monoclonal antibody |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013120394A1 (en) | 2013-08-22 |
| CN102998455B (en) | 2016-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Maula et al. | Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region | |
| US9255142B2 (en) | Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof | |
| HUP0102992A2 (en) | Antibodies to the ed-b domain of fibronectin, conjugates containing them and use therefor for diagnosis and therapy of tumors and diseases associated with angiogenesis | |
| CN102998455B (en) | The kit of a kind of detection or diagnosing prostate cancer | |
| CN103267850B (en) | Probe for pathological diagnosis of tumor, and preparation method and application thereof | |
| CN110187113A (en) | A kind of autoantibody joint-detection ELISA kit for esophageal squamous cell carcinoma early screening | |
| CN102405413A (en) | Detection of fibrin and fibrinogen degradation products and associated methods of production and use for the detection and monitoring of cancer | |
| US20180230535A1 (en) | Methods of tagging particles for multiplexed functional screening | |
| CN102687011A (en) | Cancer biomarker and the use thereof | |
| CN204789589U (en) | Colloidal gold test paper strip | |
| CN102175870A (en) | Method for increasing sensitivity of latex reagent by crosslinking latex microspheres | |
| Bergman et al. | Clinical usefulness of serum assays of neuron-specific enolase, carcinoembryonic antigen and CA-50 antigen in the diagnosis of lung cancer | |
| CN105717147B (en) | A kind of cancer risk assessment kit being directed to Chinese city population Lung neoplasm crowd based on CT images and biomarker spectrum | |
| CN109690313A (en) | Use method existing for mycobacteria substance at least two antigen test samples | |
| CN110187111A (en) | One kind being used for early cardiac cancer screening ELISA kit | |
| Anunobi et al. | Expression of the SIBLINGs and their MMP partners in human benign and malignant prostate neoplasms | |
| CN111505300B (en) | Early esophageal cancer joint screening test strip | |
| CN105492907A (en) | Novel assay | |
| CA2992370A1 (en) | Imaging device and method for detection of disease | |
| CN105682689B (en) | For detecting the diagnostic device of disease correlation target structure | |
| CN107144688B (en) | CD19 positive excretion bodies are as application of the molecular labeling in preparing tumor diagnosis kit and kit | |
| CN106279403B (en) | A kind of composition, kit and method detecting natural lung cancer associated antibodies | |
| US20080095805A1 (en) | Method Of Detecting Cancer Based On Immune Reaction To Boris | |
| JP2022104553A (en) | TEST KIT FOR URINARY EPITHELIAL CANCER IDENTIFYING Neu5Gc IN URINE MODIFIED WITH UMOD BASED ON LIP, AND MANUFACTURING METHOD FOR THE SAME | |
| Zhang et al. | Programming an antibody-peptide sandwich procedure for selectivity and ultrasensitive detection of fibrin using double-stranded DNA (dsDNA) hemp string probe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |